• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用双荧光技术通过溴脱氧尿苷测定浆细胞标记指数。

Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique.

作者信息

Lokhorst H M, Boom S E, Bast B J, Ballieux R E

出版信息

Br J Haematol. 1986 Oct;64(2):271-5. doi: 10.1111/j.1365-2141.1986.tb04119.x.

DOI:10.1111/j.1365-2141.1986.tb04119.x
PMID:3535868
Abstract

A new technique is described in which plasma cells actively synthesizing DNA can be identified in a heterogeneous cell population such as bone marrow. This method uses bromodeoxyuridine (BrdU) and a fluorescent monoclonal antibody against BrdU in combination with cytoplasmic staining for immunoglobulin (Ig). In 26 patients with monoclonal gammopathy (MG) the plasma cell labelling index (LI) as determined by this immunofluorescent method was compared with the tritiated thymidine (3H-TdR) LI. No difference in sensitivity was found between the two methods. As the determination of the plasma cell LI with the BrdU/anti BrdU method is easy to perform and results can be obtained within 4 h, this immunofluorescent method seems to be an attractive alternative to the laborious time-consuming classic 3H-TdR LI.

摘要

本文描述了一种新技术,利用该技术可在诸如骨髓等异质性细胞群体中识别出正在积极合成DNA的浆细胞。该方法使用溴脱氧尿苷(BrdU)和抗BrdU荧光单克隆抗体,并结合免疫球蛋白(Ig)的细胞质染色。对26例单克隆丙种球蛋白病(MG)患者,采用这种免疫荧光法测定的浆细胞标记指数(LI)与氚标记胸腺嘧啶核苷(3H-TdR)LI进行了比较。两种方法在敏感性上未发现差异。由于采用BrdU/抗BrdU方法测定浆细胞LI易于操作,且4小时内即可获得结果,因此这种免疫荧光法似乎是替代耗时费力的经典3H-TdR LI的一种有吸引力的方法。

相似文献

1
Determination of the plasma cell labelling index with bromodeoxyuridine in a double fluorescence technique.采用双荧光技术通过溴脱氧尿苷测定浆细胞标记指数。
Br J Haematol. 1986 Oct;64(2):271-5. doi: 10.1111/j.1365-2141.1986.tb04119.x.
2
DNA-synthesizing cells in oral epithelium have a range of cell cycle durations: evidence from double-labelling studies using tritiated thymidine and bromodeoxyuridine.口腔上皮中进行DNA合成的细胞具有一系列细胞周期持续时间:来自使用氚标记胸腺嘧啶核苷和溴脱氧尿苷的双标记研究的证据。
Cell Tissue Kinet. 1989 Sep;22(5):377-82. doi: 10.1111/j.1365-2184.1989.tb00222.x.
3
Double labelling of cells with tritiated thymidine and bromodeoxyuridine reveals a circadian rhythm-dependent variation in duration of DNA synthesis and S phase flux rates in rodent oral epithelium.用氚标记胸腺嘧啶核苷和溴脱氧尿苷对细胞进行双重标记,揭示了啮齿动物口腔上皮细胞中DNA合成持续时间和S期通量率的昼夜节律依赖性变化。
Cell Tissue Kinet. 1990 Jul;23(4):313-23. doi: 10.1111/j.1365-2184.1990.tb01127.x.
4
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.意义未明的单克隆丙种球蛋白病和冒烟型多发性骨髓瘤
Hematol Oncol Clin North Am. 2014 Oct;28(5):775-90. doi: 10.1016/j.hoc.2014.06.005. Epub 2014 Jul 22.
5
Determination of plasma cell labelling index with bromodeoxyuridine using a double immunoenzymatic technique.使用双免疫酶技术通过溴脱氧尿苷测定浆细胞标记指数。
Stain Technol. 1990;65(1):31-6. doi: 10.3109/10520299009105605.
6
Plasma cell proliferation in monoclonal gammopathies: measurement using BU-1 antibody in flow cytometry and microscopy: comparison with serum thymidine kinase.单克隆丙种球蛋白病中的浆细胞增殖:流式细胞术和显微镜检查中使用BU-1抗体进行测量:与血清胸苷激酶的比较
J Clin Pathol. 1995 May;48(5):477-81. doi: 10.1136/jcp.48.5.477.
7
Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU-1).使用单克隆抗体(BU-1)的免疫荧光浆细胞标记指数(LI)。
Am J Hematol. 1985 Nov;20(3):289-92. doi: 10.1002/ajh.2830200311.
8
Low plasma cell 3(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS), smouldering myeloma and remission phase myeloma: a reliable indicator of patients not requiring therapy.意义未明的单克隆丙种球蛋白病(MGUS)、冒烟型骨髓瘤和缓解期骨髓瘤中低浆细胞3(H)胸苷掺入:无需治疗患者的可靠指标
Br J Haematol. 1984 Dec;58(4):689-96. doi: 10.1111/j.1365-2141.1984.tb06116.x.
9
BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.BrdU 掺入多参数流式细胞术:多发性骨髓瘤中一种新的细胞周期评估方法。
Cytometry B Clin Cytom. 2019 May;96(3):209-214. doi: 10.1002/cyto.b.21730. Epub 2018 Nov 12.
10
Tracer dose and availability time of thymidine and bromodeoxyuridine: application of bromodeoxyuridine in cell kinetic studies.胸苷和溴脱氧尿苷的示踪剂量及有效时间:溴脱氧尿苷在细胞动力学研究中的应用
Cell Tissue Kinet. 1990 May;23(3):169-81. doi: 10.1111/j.1365-2184.1990.tb01113.x.

引用本文的文献

1
Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma.异常的 PTBP1 表达可维持多发性骨髓瘤的疾病进展。
Dis Markers. 2020 Jun 18;2020:4013658. doi: 10.1155/2020/4013658. eCollection 2020.
2
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.L型氨基酸转运体1(LAT1)在多发性骨髓瘤中作为预后和治疗指标的表达
Cancer Sci. 2014 Nov;105(11):1496-502. doi: 10.1111/cas.12529. Epub 2014 Oct 9.
3
Induction of malignant plasma cell proliferation by eosinophils.
嗜酸性粒细胞诱导恶性浆细胞增殖。
PLoS One. 2013 Jul 22;8(7):e70554. doi: 10.1371/journal.pone.0070554. Print 2013.
4
Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.初诊多发性骨髓瘤患者初始治疗后浆细胞增殖减少可衡量治疗反应并预测改善生存。
Blood. 2011 Sep 8;118(10):2702-7. doi: 10.1182/blood-2011-03-341933. Epub 2011 Jul 12.
5
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.增殖是多发性骨髓瘤中独立的核心预后因素和个性化及风险适应性治疗的靶点。
Haematologica. 2011 Jan;96(1):87-95. doi: 10.3324/haematol.2010.030296. Epub 2010 Sep 30.
6
Novel type of proliferating lymphoplasmacytoid cell with a characteristic spotted immunofluorescence pattern.具有特征性斑点状免疫荧光模式的新型增殖性淋巴浆细胞样细胞。
J Clin Invest. 1987 May;79(5):1401-11. doi: 10.1172/JCI112968.
7
Two-colour immunoenzymatic technique using sequential staining by APAAP to evaluate two cell antigens.采用碱性磷酸酶抗碱性磷酸酶(APAAP)顺序染色的双色免疫酶技术来评估两种细胞抗原。
J Clin Pathol. 1992 Mar;45(3):206-9. doi: 10.1136/jcp.45.3.206.